Loteprednol Etabonate 0.5% Ophthalmic Suspension
Last Updated: March 20, 2014
Products Affected - Description
Lotemax 0.5% ophthalmic suspension, Bausch & Lomb, Division of Valeant Pharmaceuticals
5 mL bottle (NDC 24208-0299-05) - discontinued
10 mL bottle (NDC 24208-0299-10) - discontinued
15 mL bottle (NDC 24208-0299-15) - discontinued
Reason for the Shortage
- Valeant Pharmaceuticals discontinued Lotemax 0.5% ophthalmic suspension in February 2014 because of the anticipated release of the generic product in April 2014.
- Valeant Pharmaceuticals acquired Bausch & Lomb in August 2013.
- Supplies of Alrex (loteprednol 0.2% ophthalmic suspension) and Zylet (loteprednol 0.5% and tobramycin 0.3% ophthalmic suspension) are not affected and continue to be available.
Lotemax 0.5% ophthalmic gel, Bausch & Lomb, Division of Valeant Pharmaceuticals
5 grams in 10 mL bottle (NDC 24208-0503-07)
Lotemax 0.5% ophthalmic ointment, Bausch & Lomb, Division of Valeant Pharmaceuticals
3.5 gram tube (NDC 24208-0443-35)
Estimated Resupply Dates
All presentations are currently available.
March 20, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.